ERBB2 and colorectal carcinoma: A combination of trastuzumab with lapatinib, an EGFR and HER2 tyrosine kinase inhibitor (TKI), has shown an improved response in previously treated RAS wild-type, HER2-positive metastatic CRC patients in the phase II trial HERACLES-A, with an overall response rate (ORR) of 30%, a median progression-free survival (PFS) of 9.5 months, and a median OS of 11.5 months [17].